Efficacy and safety of Risankizumab in moderate to severe psoriasis: A systematic review and meta-analysis.

Singh, Surjit; Singh, Saurabh; Thangaswamy, Abisha; Thangaraju, Pugazhenthan; Varthya, Shoban Babu

Singh, Surjit; Singh, Saurabh; Thangaswamy, Abisha; Thangaraju, Pugazhenthan; Varthya, Shoban Babu.

Afiliación

Singh S; Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India.
Singh S; Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences, Jodhpur, India.
Thangaswamy A; Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India.
Thangaraju P; Department of Pharmacology, All India Institute of Medical Sciences, Raipur, India.
Varthya SB; Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India.

Dermatol Ther ; 34(1): e14487, 2021 01.

Article en En | MEDLINE | ID: mdl-33140468

Asunto(s)

Anticuerpos Monoclonales; Psoriasis; Anticuerpos Monoclonales/efectos adversos; Humanos; Psoriasis/diagnóstico; Psoriasis/tratamiento farmacológico; Índice de Severidad de la Enfermedad; Resultado del Tratamiento

Palabras clave

Risankizumab; plaque psoriasis; systematic review

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Psoriasis / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Dermatol Ther Asunto de la revista: DERMATOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: India

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google